Tiger Brokers

Arcadia Biosciences FY2025 net loss attributable to common stockholders narrows 67% to $2.3 million; revenue drops 4% to $4.9 million

Reuters
Mar 27
Arcadia Biosciences FY2025 net loss attributable to common stockholders narrows 67% to $2.3 million; revenue drops 4% to $4.9 million
  • Arcadia Biosciences filed a Form 8-K reporting Q4 and FY 2025 results, including Q4 total revenues of 901,000 USD, down 26%.
  • FY total revenues were 4.86 million USD, down 4%, as higher Zola revenues were offset by no GLA oil sales.
  • Q4 net loss attributable to common stockholders was 1.34 million USD, compared with a net loss of 4.06 million USD a year earlier.
  • FY net loss attributable to common stockholders was 2.34 million USD, compared with a net loss of 7.04 million USD a year earlier.
  • Management said it received a termination notice from Roosevelt Resources related to the proposed business combination and secured 2.1 million USD in gross proceeds from the immediate exercise of certain preferred investment options to support Zola growth while evaluating strategic alternatives.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcadia Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-126220), on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10